The aim ofthis study was to determine the effect of surfactant treatment on the number and distribution of inflammatory cells in bronchoalveolar lavage fluid (BALF) from mechanically ventilated preterm infants over the first week of life in relation to the subsequent development of chronic lung disease (CLD). The study included 25 babies who received surfactant on clinical grounds and 29 babies of similar severity who did not. BALF was collected on days 1, 3, 5, and 7 after birth. Cell counts were performed and differentials were calculated on 300 cells. CLD was equally common in both treatment groups. Of the 54 infants, 29 (53°/0) who developed CLD had a higher incidence of patent ductus arteriosus and air leak and needed a higher concentration of inspired oxygen on the fifth and seventh days of life. Babies who developed CLD had more polymorphonuclear leucocytes and fewer macrophages on days 5 and 7 than those who recovered. Surfactant treatment was associated with a higher total white cell count on day 3. Between days 3 and 7, macrophage numbers were higher in surfactant treated babies, whatever the pulmonary outcome. This data suggests that CLD was associated with persistence of high numbers of polymorphonuclear leucocytes in BALF at the end of the first week. Surfactant treatment caused a persistent increase in macrophage numbers. The association between persistent neutrophilia and CLD was unaffected by surfactant treatment.
Since the introduction of the term bronchopulmonary dysplasia by Northway,' attempts have been made to identify features which might distinguish those preterm infants who subsequently develop chronic lung disease (CLD) of prematurity from those who recover from the initial phase of respiratory distress syndrome. Several groups have attempted to do this by examining the numbers and distribution of inflammatory cells obtained by bronchoalveolar lavage during the first weeks of life.2 3 Under experimental conditions, inflammatory cells obtained by bronchoalveolar lavage have been used as a marker of lung damage and repair. Before analysis, BALF cell counts were log transformed from a skewed to a normal distribution. Discrete variables were compared by unpaired t test with Bonferoni correction for multiple comparisons. We did not attempt to divide the surfactant patients into small subsets according to therapeutic group (high or low dose) because of the small numbers involved.
Results
Of the 54 infants, 29 (53%) developed CLD according to the above criteria, 15/29 control infants and 14/25 who had received surfactant. Babies who developed CLD had a higher incidence of patent ductus arteriosus and air leak, and needed a higher concentration of inspired oxygen on the fifth (table) and seventh days of life (p<0 05). There were few significant differences between the surfactant and non-surfactant treated infants except for the higher first day mean peak inspiratory pressure and subsequently a higher incidence of clinically diagnosed patent ductus arteriosus requiring diuretic or indomethacin treatment in the surfactant group (table). There was no significant difference in mean inspired oxygen concentration, ventilatory rate, or level of positive end expiratory pressure in the first week of life, between the two groups.
Beyond the one week sampling period, most infants received a course of dexamethasone; those who subsequently developed CLD had a greater incidence of bacterial sepsis (positive blood, urine, or cerebrospinal fluid culture) beyond the sampling period of one week (table) .
BRONCHOALVEOLAR LAVAGE
The volume of fluid recovered did not vary between groups or between study days. The overall mean (SD) proportion recovered from over 200 bronchoalveolar lavage procedures was 55-5 (7-6)%, with a mean volume of 1-1 ml/kg. All samples were bacteriologically sterile. The numbers of samples rejected because of bloodstaining or small volume was 19 out of a total of 216 samples.
There was no difference in the total number of inflammatory cells between babies who developed CLD and those who did not. However, babies who developed CLD had more polymorphonuclear leucocytes and fewer macrophages on days 5 and 7 than those who recovered without CLD (fig 1) . Surfactant treatment had a significant effect on the BALF cell population on days 3-5 (fig 2) . Total cell counts as well as polymorphonuclear greater in the treatment group on day 3, the higher macrophage count persisting until day 5. Postnatal age (days) We did not include babies with pre-existing lung conditions such as overt or suspected infection, which could have influenced the inflammatory cell population in the lung. To do so would have rendered the surfactant and control groups non-comparable, as surfactant would not routinely be given to babies with lung disease of infective origin. Although the groups were sequential rather than being based on random assessment of subjects, they were closely comparable before surfactant administration. Over the limited 12 month period of the study, management protocols other than those involving surfactant therapy, had not altered. Thus, although the study did not have randomised design, we feel that the results are valid.
BALF INFLAMMATORY CELLS
Jacob and coworkers previously reported in newborn monkeys that macrophage numbers were low in utero and increased markedly in the postnatal period in term monkeys without hyaline membrane disease.8 They did not increase postnatally in monkeys with hyaline membrane disease that had persistent deficiency in phospholipid surface active material in BALF. Either a common determinant could cause both the increase in alveolar surface active material and in macrophage number, or the increase in one may lead to the increase in the other.16 17 Our study strongly suggests that very soon after administration of an exogenous natural surfactant preparation, macrophage numbers increase in BALF. The rapidity of the change implies a specific chemoattractant effect. In our study the surfactant used was a natural extract, prepared from minced porcine lung. It contained 99% polar lipids, predominantly phospholipid, and only 1% lipophilic low molecular weight proteins. ' 
